Investor Presentaiton
Rigosertib's Promising Single-agent Activity in RDEB-associated SCC
Complete remission of all cancerous skin lesions in 2 of 2 evaluable participants
RDEB-associated SCC: An ultra-rare condition
Lesions Display Clinical and Histological Remission
Following Treatment with Rigosertib
Absence of type VII collagen protein leads to
extreme skin fragility and chronic wound formation
Patients develop SCCs that arise in areas of chronic
skin inflammation
Cumulative risk of death: 78.7% by age 55
Current therapies: Limited response of short
duration
V25 (Day 169-175)
V1 (Day 1)
Left Hand
Right Elbow
13
RDEB: Recessive dystrophic epidermolysis bullosa; SCC: Squamous cell carcinoma; Source: Laimer et al. Austrian Society of Dermatology and Venerology Annual Conference 2021
ง
ONCONOVA
THERAPEUTICSView entire presentation